Trials / Terminated
TerminatedNCT02417870
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
Safety and Efficacy of Treatment With Ultra-low Dose Subcutaneous IL-2 to Promote Regulatory T Cells Post Renal Transplantation
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Anil K. Chandraker, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and tolerability of treatment with low dose rIL-2 in renal transplant recipients. To assess the immunologic impact of low dose rIL-2 in renal transplant recipients. To assess the efficacy of low dose rIL-2 in renal transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | aldesleukin |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2018-04-01
- Completion
- 2018-04-01
- First posted
- 2015-04-16
- Last updated
- 2021-06-24
- Results posted
- 2021-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02417870. Inclusion in this directory is not an endorsement.